Giulia Fulci

BG Medicine (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

26h-index2.7kcitations80works1.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(33), Herpesvirus Infections and Treatments(19), Animal Virus Infections Studies(14), CAR-T cell therapy research(12), Neurofibromatosis and Schwannoma Cases(9)

Publications80 total

Patient-reported outcomes from dreamm-7 and dreamm-8 using the EQ-5D-3L, patient global impression of severity, and patient global impression of change
Blood·2025Open Access
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial
The Lancet Haematology·2025· 1 cited
Updated Results From the Phase 3 DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025· 1 cited
Belantamab for the Treatment of Multiple Myeloma: Results from Part 1 of the First-in-Human Phase 1/2 DREAMM-20 Trial
Clinical Lymphoma Myeloma & Leukemia·2025
Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Comprehensive Exposure-Response Analysis of the DREAMM-8 Study
Targeted Oncology·2025Open Access
Belantamab treatment of multiple myeloma: Results from part 1 of the first-in-human phase 1/2 DREAMM-20 trial.
Journal of Clinical Oncology·2025
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide
Blood·2024· 5 cited
92 High-dimensional, single-cell analysis and transcriptional profiling reveal novel correlatives of response to PARP inhibition plus PD-1 blockade in triple-negative breast cancer
Regular and Young Investigator Award Abstracts·2024· 1 citedOpen Access
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).
Journal of Clinical Oncology·2024· 9 cited
P-305 DREAMM-20: a study to investigate the safety and efficacy of belantamab for the treatment of multiple myeloma (MM) when used as monotherapy and in combination treatments
Clinical Lymphoma Myeloma & Leukemia·2023
P983: DREAMM-20: A STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF BELANTAMAB FOR THE TREATMENT OF MULTIPLE MYELOMA WHEN USED AS MONOTHERAPY AND IN COMBINATION TREATMENTS
HemaSphere·2023· 1 citedOpen Access
Data from Distinguishing Inflammation from Tumor and Peritumoral Edema by Myeloperoxidase Magnetic Resonance Imaging
2023Open Access
Supplementary Figures S1-S3 from Distinguishing Inflammation from Tumor and Peritumoral Edema by Myeloperoxidase Magnetic Resonance Imaging
2023Open Access
Supplementary Figures S1-S3 from Distinguishing Inflammation from Tumor and Peritumoral Edema by Myeloperoxidase Magnetic Resonance Imaging
2023Open Access
Data from Distinguishing Inflammation from Tumor and Peritumoral Edema by Myeloperoxidase Magnetic Resonance Imaging
2023Open Access
Supplementary Figure 1B from Depletion of Peripheral Macrophages and Brain Microglia Increases Brain Tumor Titers of Oncolytic Viruses
2023Open Access
Supplementary Figure 2 from Depletion of Peripheral Macrophages and Brain Microglia Increases Brain Tumor Titers of Oncolytic Viruses
2023Open Access
Data from Depletion of Peripheral Macrophages and Brain Microglia Increases Brain Tumor Titers of Oncolytic Viruses
2023Open Access
Supplementary Figure 1A from Depletion of Peripheral Macrophages and Brain Microglia Increases Brain Tumor Titers of Oncolytic Viruses
2023Open Access
Supplementary Figure 1A from Depletion of Peripheral Macrophages and Brain Microglia Increases Brain Tumor Titers of Oncolytic Viruses
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Ralph Weissleder(8), E. Antonio Chiocca(8), Erwin G. Van Meir(7), Martine L.M. Lamfers(7), D. Gareth Evans(7), Rosalie E. Ferner(7), Staci Martin(7), Balveen Kaur(6), Shivani Ahlawat(6), Laura M. Fayad(6), Miriam A. Bredella(6), Gordon J. Harris(6), Michael A. Jacobs(6), Eva Dombi(6), Wenli Cai(6), Srivandana Akshintala(6), Andrea Baldwin(6), Amanda L. Bergner(6), Peter de Blank(6), William N. Dudley(6)